New method for detecting MicroRNA in breast cancer patients
A New Detection Method for MicroRNA in Patients With Breast Cancer
Tongji Hospital · NCT06529614
This study is testing a new way to detect MicroRNA in the blood of breast cancer patients to see if it can help track the disease and how well treatments are working.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Tongji Hospital (other) |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06529614 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on developing a novel in-situ detection method for MicroRNA in the serum of patients diagnosed with breast cancer. The approach aims to improve the accuracy of MicroRNA detection, which could enhance the understanding of breast cancer progression and treatment response. By analyzing serum samples, the study seeks to establish a reliable biomarker for monitoring the disease. The methodology involves collecting serum samples from participants and applying the new detection technique to assess MicroRNA levels.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with breast cancer who are healthy otherwise and do not have serious comorbidities.
Not a fit: Patients with serious diseases or conditions that may interfere with the results of the MicroRNA detection will not benefit from this study.
Why it matters
Potential benefit: If successful, this method could provide a more accurate and non-invasive way to monitor breast cancer progression and treatment efficacy.
How similar studies have performed: While there have been studies exploring MicroRNA detection in cancer, this specific in-situ detection method is novel and has not been widely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Healthy without serious diseases \- Exclusion Criteria: * situations that may affect the results
Where this trial is running
Wuhan, Hubei
- Tongji Hospital — Wuhan, Hubei, China (RECRUITING)
Study contacts
- Study coordinator: Lei Dou, Dr.
- Email: 616732045@qq.com
- Phone: 15171473498
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer